AARHUS UNIVERSITY

Press release

Please fill in this form and return it to graduateschoolhealth@au.dk in Word format along with a portrait photo in JPEG format, if you would like it to accompany your press release, no later than three weeks prior to your defence.

Basic information

Name: Kristine Raaby Gammelgaard Email: kraaby@biomed.au.dk Phone: 24213123

Department of: Biomedicine

Main supervisor: Anders Lade Nielsen

Title of dissertation: EGFR-TKI Resistance in NSCLC - a Piece of the Unscrambled Message

Date for defence: 23.02.2018 at (time of day): 13.00 Place: Fysiologisk Aud A

Press release (Danish)

Resistens overfor targeteret behandling i Ikke-småcellet lungekræft

Targeterede behandlinger rettet mod overaktive signalveje spiller en vigtig rolle i behandlingen af ikke-småcellet lungekræft (NSCLC). Desværre udvikles der resistens mod behandlingerne over tid. Epidermal Growth Factor Receptor (EGFR) er et protein, der ofte er muteret i NSCLC, og patienter med denne mutation behandles med en EGFR-targeteret behandling. Resistens mod EGFR-targeteret behandling er emnet for et nyt ph.d.-projekt fra Aarhus Universitet, Health. Projektet er gennemført af Kristine Raaby Gammelgaard, der forsvarer det d. 23/2-2018

Forsvaret af ph.d.-projektet er offentligt og finder sted den 23/2-2018 kl. 13.00 i Fysiologisk auditorium A, Aarhus Universitet, Ole Worms allé, Aarhus C. Titlen på projektet er "EGFR-TKI Resistance in NSCLC - a Piece of the Unscrambled Message". Yderligere oplysninger: Ph.d.-studerende Kristine Raaby Gammelgaard, e-mail: kraaby@biomed.au.dk, tlf. 24213123.

Bedømmelsesudvalg:
Associate Professor Lise Lotte Hansen - Formand for udvalget og moderator af forsvaret
Department of Biomedicine, Aarhus University, Denmark

Senior Clinical Scientist & Adjunct Assistant Professor - Steven Gray, PhD Thoracic Oncology Research Group, Trinity Translational Medical Institute, Trinity Centre for Health Sciences, St James's Hospital,, Dublin, Ireland

Tuula Kallunki, PhD, Docent 2
Cell Death and Metabolism, Center for Autophagy, Recycling and Disease, Danish Cancer Society Research Center, Denmark

Professor Anders Lade Nielsen - Hovedvejleder og non-voting member af bedømmelsesudvalget
Department of Biomedicine, Aarhus University, Denmark

Press release (English)

Resistance to Targeted Treatment in NSCLC

Treatments targeting overactive pathways play an important role in the treatment of Non-Small Cell Lung Cancer (NSCLC). Unfortunately, all patients develop resistance to treatment over time. Epidermal Growth Factor Receptor (EGFR) is a protein that is often mutated and hence overactive in NSCLC. Patients harboring EGFR mutations are treated with EGFR-inhibitors. Resistance to EGFR-

inhibitors is the subject of a new PhD project from Aarhus University. The project was carried out by Kristine Raaby Gammelgaard, who is defending her dissertation on 23/2-2018.

The defence is public and takes place on 23/2-2018 at 1:00 pm in Fysiologisk Auditorium A, Aarhus University, Ole Worms allé, Aarhus C. The title of the project is EGFR-TKI Resistance in NSCLC - a Piece of the Unscrambled Message. For more information, please contact PhD student Kristine Raaby Gammelgaard, email: kraaby@biomed.au.dk, Phone +45 24213123.

Assessment committee:
Associate Professor Lise Lotte Hansen - chairman of the committee and moderator of the defence
Department of Biomedicine, Aarhus University, Denmark

Senior Clinical Scientist & Adjunct Assistant Professor - Steven Gray, PhD Thoracic Oncology Research Group, Trinity Translational Medical Institute, Trinity Centre for Health Sciences, St James's Hospital, Dublin, Ireland

Tuula Kallunki, PhD, Docent 2
Cell Death and Metabolism, Center for Autophagy, Recycling and Disease, Danish Cancer Society Research Center, Copenhagen, Denmark

Professor Anders Lade Nielsen - main supervisor, non-voting member of the committee
Department of Biomedicine, Aarhus University, Denmark

Permission

By sending in this form:

- I hereby grant permission to publish the above Danish and English press releases as well as any submitted photo.
- I confirm that I have been informed that any applicable inventions shall be treated confidentially and shall under no circumstances whatsoever be published, presented or mentioned prior to submission of a patent application, and that I have an obligation to inform my head of department and the university's Patents Committee if I believe I have made an invention in connection with my work. I also confirm that I am not aware that publication violates any other possible holders of a copyright.